Interactive worksheet
Interactive worksheet
Clinical inputs
0/12 filled
Clinical contextWhy this tool matters and how to interpret it
Understand the result,
not just the number.
References and context The ENTRUST-AF PCI randomized trial and its prespecified analyses inform antithrombotic choices for AF patients undergoing PCI. Key publications: Vranckx P, et al. ENTRUST-AF PCI (Lancet 2019) — trial report; prespecified analyses and subgroup reports are available in subsequent journal publications.
Clinicians should combine the trial evidence with individual CHA₂DS₂-VASc and HAS-BLED assessment when deciding antithrombotic regimens after PCI. Selected
Evidence & references1 primary source mapped
- Source 1
Vranckx P, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–1343. Vranckx P, et al. Prespecified analyses of ENTRUST-AF PCI: clinical predictors and subgroup outcomes. Eur Heart J. (analysis). Additional reviews and subanalyses of AF+PCI populations and bleeding/ischemic predictors also provide context for risk stratification and therapy selection.
Clinical discussionModerated, tool-specific conversation
Loading discussion…